BioSpace News Archive

LimmaTech Biologics AG signed an in-license agreement with GlaxoSmithKline Biologicals SA enabling LimmaTech Bio to further develop and commercialize a quadrivalent bioconjugate vaccine candidate for shigellosis that GSK added to its infectious disease pipeline when LimmaTech Bio’s predecessor company, GlycoVaxyn, was acquired by GSK in 2015.

Genmab A/S announced that worldwide net trade sales of DARZALEX®, including sales of the subcutaneous product, as reported by Johnson & Johnson were USD 2,431 million in the second quarter of 2023.

Johnson & Johnson announced results for second-quarter 2023. “Our robust performance in the second quarter and first half of 2023 is a testament to the hard work and commitment of our colleagues around the world,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer.

Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, August 3, 2023.

Karuna Therapeutics, Inc. announced that it will host a live conference call and webcast on Thursday, August 3, 2023 at 8:00 a.m. ET to review second quarter 2023 financial results and provide a general business update.

Eliem Therapeutics, Inc. announced that it has completed a review of its business, including the status of its programs, resources, and capabilities, and has made the determination to halt further development of its Kv7 program and to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value.

Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders and refractory epilepsy, today announced the successful completion of its three-part Phase 1 study of BMB-101.

BD, a leading global medical technology company, issued its Fiscal Year 2022 Environmental, Social and Governance Report that details ongoing efforts that impact company health, human health, community health and planet health.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2023 financial results on Thursday, August 3, 2023.

Excision BioTherapeutics, Inc. today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for its CRISPR-based therapy, EBT-101, a dual-cut CRISPR-based gene therapy for the treatment of human immunodeficiency virus type 1 (HIV-1).